| Field | Specification |
|---|---|
| Target | |
| Alternative names | Cathepsin D;3.4.23.5;Ctsd; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived mouse Cathepsin D recombinant protein (Position: E65-L410). Mouse Cathepsin D shares 85% and 91% amino acid (aa) sequences identity with human and rat Cathepsin D, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects cathepsin D (gene Ctsd) in mouse and rat samples and is validated for Western blot, IHC and flow cytometry. The predicted molecular weight is 45.0 kDa, and the supplier reports an observed band at about 45 kDa.
Cathepsin D (CTSD) is a lysosomal aspartic protease that carries out bulk breakdown of proteins in acidic compartments. It also participates in processing of proteins such as amyloid precursor protein. CTSD is studied in lysosomal function, neurodegeneration and breast cancer, where its secretion has been widely investigated.
| Target | Cathepsin D (gene Ctsd; UniProt P18242, mouse) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.01 mg NaN3; plus stabilizers |
| Calculated MW | 45.0 kDa |
| Observed MW | 45 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Mouse) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Mouse, Rat) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Mouse) |
Samples with a confirmed band (WB): mouse liver tissue, mouse brain tissue, mouse thymus tissue, NEURO cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): mouse kidney tissue, mouse liver tissue, rat liver tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with a confirmed signal (flow cytometry): mouse liver tissue.
Immunogen
Recombinant mouse Cathepsin D fragment (Glu65–Leu410), expressed in E. coli. Sequence identity with the human and rat orthologs: 85% and 91%, respectively.
Reactivity Notes
The supplier lists reactivity with mouse and rat. UniProt describes cathepsin D as secreted and also located in the lysosome and melanosome. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Alexey A. Kulikov et al. (2022) Dynamics of neurodegeneration in the hippocampus of Krushinsky-Molodkina rats correlates with the progression of limbic seizures. Epilepsy & Behavior. 10.1016/j.yebeh.2022.108846
